Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,273.47 -4.04 (-0.08%) Dow
38,479.03 -207.29 (-0.54%) Nasdaq
16,796.79 +61.77 (+0.37%) Bitcoin USD
69,242.59 +1,252.20 (+1.84%) CMC Crypto 200
1,483.42 +15.48 (+1.06%)
PMVP Jun 2024 2.500 put
| Previous close | 0.6200 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 1.1500 |
| Strike | 2.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.6200 - 0.6200 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksHere's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
GlobeNewswirePMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies
- GlobeNewswire
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP5
